+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Use of research biopsies in clinical trials: are risks and benefits adequately discussed?

Use of research biopsies in clinical trials: are risks and benefits adequately discussed?

Journal of Clinical Oncology 31(1): 17-22

Although the incorporation of research biopsies into clinical trials is increasing, limited information is available about how study protocols and informed consents integrate and describe their use. All therapeutic clinical trials in which image-guided research biopsies were performed from January 1, 2005, to October 1, 2010, were identified from an interventional radiology database. Data from study protocols and informed consents were extracted and analyzed. Procedural complications were recorded. A total of 57 clinical trials were identified, of which 38 (67%) contained at least one mandatory biopsy. The analysis of the research biopsy tumor tissue was a study end point in 95% of trials. The primary indication for a research biopsy was for integral biomarker analysis in 32% and for correlative science in 68% of trials. A statistical analytic plan for the correlative science research biopsy tumor tissue was mentioned in 26%, described as exploratory in 51%, and not mentioned in 23% of trials. For studies with mandatory biopsies, biopsy was an eligibility criterion in 71% of trials, and a statistical justification for the research biopsy sample size was present in 50% of trials. A total of 745 research biopsies were performed on 576 patients. Overall and major complication rates were 5.2% (39 of 745 biopsies) and 0.8% (six of 745 biopsies), respectively. Complication rates for intrathoracic and abdominal/pelvic solid organ biopsies were 17.1% (36 of 211 biopsies) and 1.6% (three of 189 biopsies), respectively. Site-stratified research biopsy-related risks were discussed in five consents. A better representation of the risks and benefits of research biopsies in study protocols and informed consents is needed.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 036662919

Download citation: RISBibTeXText

PMID: 23129736

DOI: 10.1200/jco.2012.43.1718

Related references

A framework for analysis of research risks and benefits to participants in standard of care pragmatic clinical trials. Clinical Trials 13(6): 605-611, 2016

Assessment of Reported Trial Characteristics, Rate of Publication, and Inclusion of Mandatory Biopsies of Research Biopsies in Clinical Trials in Oncology. JAMA Oncology 5(3): 402-405, 2019

Risks (and benefits) in comparative effectiveness research trials. New England Journal of Medicine 369(10): 892-894, 2013

Does the new EU Regulation on clinical trials adequately protect vulnerable research participants?. Health Policy 119(7): 925-931, 2015

Clinical trials: risks and benefits. Seminars in Pediatric Surgery 11(3): 156-60; Discussion 160-1, 2002

Cancer clinical trials: risks and benefits. Journal of Pediatric Hematology/Oncology 23(9): 564-567, 2001

Defining benefits and risks for SERMs in clinical trials and clinical practice. Annals of the new York Academy of Sciences 949: 304-314, 2001

Standardization of retinopathy of prematurity clinical examinations in clinical trials: risks, benefits and alternatives. Clinical and Experimental Ophthalmology 36(1): 1-2, 2008

Commercializing clinical trials--risks and benefits of the CRO boom. New England Journal of Medicine 357(14): 1365-1368, 2007

Number-needed-to-treat: translating benefits and risks of therapy from clinical trials to a clinical encounter. Journal of Physician Assistant Education 24(1): 45-49, 2013

Generating new evidence, improving clinical practice and developing research capacity: the benefits of recruiting to the U.K. Dermatology Clinical Trials Network's STOP GAP and BLISTER trials. British Journal of Dermatology 177(5): E228-E234, 2017

Decision theory and the evaluation of risks and benefits of clinical trials. Drug Discovery Today 17(23-24): 1263-1269, 2012

Weighing the benefits and risks in clinical trials and practice Introduction. Anthony, Marietta , Dunn, Barbara K , Sherman, Sherry Annals of the New York Academy of Sciences Selective estrogen receptor modulators (SERMs) 279, 2001

Perspectives on assessing benefits and risks in clinical trials for Alzheimer's disease. Alzheimer's and Dementia 2(3): 160-163, 2006

Trends in the risks and benefits to patients with cancer in phase 1 clinical trials. JAMA 293(7): 795; Author Reply 795, 2005